Physician profile
Bipin Kumar
NPI 1710939376
$1,583.75
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $220 · 2021: $48.55 · 2022: $189 · 2023: $31.88 · 2024: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $312.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $253.11 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $221.00 | 2024 | Voquezna |
| Novo Nordisk INC | $216.21 | 2019-2024 | Ozempic |
| Amarin Pharma, INC. | $166.44 | 2019 | |
| Janssen Pharmaceuticals, INC | $166.26 | 2020 | |
| Astellas Pharma US INC | $151.94 | 2019 | |
| Alexion Pharmaceuticals, INC. | $100.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $87.72 | 2019 | |
| Amgen INC. | $80.99 | 2019 | |
| Lilly USA, LLC | $73.28 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.73 | 2024 | Rexulti |
| Paratek Pharmaceuticals, INC. | $17.46 | 2023 | Nuzyra |
| Philips North America LLC | $15.19 | 2024 | (Cm9) Amb Mon & Diag Und |
| Abbvie INC. | $14.42 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bipin Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.